motor development is clearly recognised in association with PNP deficiency, often being the presenting feature. The characteristics of these motor disorders have not been clearly defined, however, with previous papers referring to spastic quadriplegia or spastic diplegia. 2 3

Two siblings described as having familial dysequilibrium/diplegia with T lymphocyte deficiency have now retrospectively been found to have PNP deficiency, using cultured fibroblasts, at this hospital. Both parents had heterozygote values for PNP. These children were thought to be similar to those described by Hagberg et al as having familial ataxic diplegia with deficient cellular immunity. 3 The four children described in these two papers, plus our own case, point to a fairly characteristic and identifiable clinical picture. This would seem to consist of a dysequilibrium—that is, pronounced difficulty in maintaining posture and upright position giving rise to an early hypotonia, very unsteady and delayed sitting, and great difficulty in walking independently. In contrast there is either no, or only a mild, intention tremor or clumsiness. There is evidence of a spastic diplegia on clinical examination with brisk reflexes, upgoing plantars, and sometimes ankle clonus and restriction of passive dorsiflexion of the ankles. When walking this is masked by truncal ataxia, however, particularly as the child gets older. The neurological picture appears to be non-progressive, may relate to the degree of guanosine triphosphate depletion and is non-infective in aetiology. 2 Intelligence may be normal as in this case.

The haematological and immunological consequences of PNP deficiency relate to the depressed T cell numbers and function, leading to repeated infections with viral illnesses often being the cause of death. These children should not receive live vaccinations. Lymphomas, often of a B cell origin, are also a complication of other immunodeficiency states, for example, AIDS, and have been described in PNP deficiency. 3 Haematological findings in PNP deficiency are pure red cell aplasia, megaloblastic anaemia, autoimmune haemolytic anaemia, 4 5 and maturational arrest at the myelocyte/metamyelocyte stage in bone marrow aspirates. 3 Intracytoplasmic neutrophil inclusions (figure) have not been previously described; they persisted after resolution of sepsis and in addition, identical inclusions were seen in the paternal blood film. Similar inclusions are well recognised during treatment with drugs that interfere with DNA synthesis such as azathioprine, chlorambucil, and appear to be fragments of DNA. DNA synthesis is impaired in PNP deficiency suggesting a similar aetiology.

Autoimmune disease is another complication of immune deficiency including PNP deficiency. 4 Suspecting the neutropenia to be immune mediated, we treated our patient with 2 g/kg intravenous immunoglobulin over two days. There followed a dramatic rise in the neutrophil count (0-4–2.8*10^9/l). The patient had been persistently neutropenic for two months before this.

In conclusion, recognition of PNP deficiency before onset of severe infection or malignancy is important so that bone marrow transplantation from a suitable donor can be considered while the patient is well. Successful engraftment has already been documented in this condition. 1 6 In addition, antenatal diagnosis is now possible for measuring PNP in chorionic villus samples.

We consider familial dysequilibrium/diplegia with T lymphocyte deficiency and familial ataxic diplegia with deficient cellular immunity should no longer be considered separate disease entities, but reclassified as cases of PNP deficiency.

We thank Mr R Webber for his photographic and technical assistance.


Fulminant hepatitis B in an infant born to a hepatitis B antibody positive, DNA negative carrier

J Vanclaire, Ch Cornu, E M Sokal

Abstract

A boy was born to a mother who was a chronic hepatitis B virus (HBV) carrier. She was hepatitis B (HBe) antibody positive and HBe antigen and HBV-DNA negative. The boy had not received hepatitis B vaccine and died from fulminant hepatitis at 3 months of age. This case demonstrates the need to vaccinate babies of HBe antibody positive, HBe antigen negative carriers.
Perinatal transmission of hepatitis B virus (HBV) is well documented in babies born to hepatitis B (HBe) antigen positive mothers.\(^1\) Risk of contamination as well as natural history when the mother is HBe antigen negative is underestimated, however, and these babies are not always given HBV vaccination. We report the case of a child who died from fulminant hepatitis B and who was born to an HBe antigen and DNA negative mother.

**Case report**

A boy was born at full term to a healthy HBV carrier. She was hepatitis B surface (HBs) antigen positive, HBe antigen negative, hepatitis B core (HBc) IgG antibody positive, HBe antibody positive, and HBV-DNA negative. The boy was not vaccinated and did not receive immune prophylaxis at birth. He had no contact with any other known HBV carrier.

At 3 months old he was admitted to hospital because of vomiting, failure to thrive, jaundice, and hepatomegaly. He was irritable. Liver and spleen were not palpable and he had mild ascites. Biochemical investigations are shown in the table. He was Hbc IgM antibody positive, HBs antigen positive, HBe antigen negative, and HBe antibody positive. Serology for hepatitis A virus, cytomegalovirus, Epstein-Barr virus, HIV, and toxoplasmosis were negative. He had passive immunisation for rubella and herpes simplex virus. His urine was sterile. He had received no sucrose and no drugs, and urinary reducing substances were negative. Erythrocyte uridyldiphosphate galactosyl transferase activity and serum tyrosine concentrations were normal. Liver ultrasonography showed appreciable parenchymal atrophy, normal biliary tract, and ascites. He was registered on the urgent list for liver transplantation and was admitted to the intensive care unit. Within 24 hours his condition deteriorated, encephalopathy progressed, and he died from liver insufficiency.

His mother’s HBV serological markers were identical to those at her prenatal investigations and there was no HBV-DNA detected in serum by liquid phase molecular hybridisation (Abbott).

**Discussion**

It is commonly thought that the risk of HBV transmission is absent or low when the hepatitis B carrier mother has developed anti-HBe antibodies.\(^2\) Because of this, babies born from these mothers may not be vaccinated at birth against hepatitis B in developed countries. The risk of perinatal transmission is related to HBs antigen titre, HBe antigen positivity, and HBV specific DNA or DNA polymerase activity in maternal serum.\(^1\)\(^2\) However, case reports have shown that anti-HBe antibodies do not protect fully against HBV transmission, and to 10 to 20% of babies born to HBs antigen positive, HBe antibody positive mothers may be infected.\(^3\)\(^4\)

In one series half of these developed acute or even fatal hepatitis B.\(^4\) It is not known if maternal serum contained HBV-DNA in these cases. The present report demonstrates that even when no HBV-DNA is detected by hybridisation in serum of HBs antigen positive mothers, babies are at risk of developing postnatal hepatitis B. Mild viral replication can be present despite negativity of serum HBs antigen and HBV-DNA,\(^4\) and it is likely that the baby was contaminated with maternal serum containing traces of HBV-DNA that was not detectable by DNA hybridisation. The child had had no contact with any other HBV carrier.

It is not known why when the mother is HBe antigen negative and HBs antigen positive the risk is greater of developing a severe or even fulminant hepatitis than in babies born from HBe antigen positive mothers.\(^3\)\(^4\) The host immunological response to infection is responsible for the hepatocellular lysis instead of the virus itself. Infants from HBe antigen negative mothers may be exposed to low doses of HBV particles and may develop an overwhelming response to infection causing massive immune mediated damage. On the other hand infants from HBe antigen positive mothers receive a lot of HBV. The capacity of their immune system to fight the infection might be exceeded and they do tend to become chronic asymptomatic carriers.\(^3\)\(^4\) It has also been suggested that HBV mutation may modify the course of chronic hepatitis and might prevent formation of normal HBe antigen.\(^4\) If this was the case in our patient we would have expected to find HBV-DNA in maternal serum.

No other cause of liver disease was found in our patient. Although liver transplantation has not been performed in this particular situation in infants, the procedure can be successful in small children and the boy was therefore registered on the waiting list.\(^7\) He unfortunately died before any donor could be found.

Our case report shows that HBe antibodies do not protect against perinatal HBV mother to child transmission, and that babies from HBe antibody positive, HBV-DNA negative carrier mothers are at risk of developing fulminant hepatitis B. They should therefore also be included in vaccination programmes against hepatitis B.

---

Fulminant hepatitis B in an infant born to a hepatitis B antibody positive, DNA negative carrier

Need for immunophrophylaxis in infants born to HBs antigen positive carrier mothers who are HBs antigen negative. 4 Chang MH, Lee CY, Chen DS, Hsu HC, Lai MY. Fulminant hepatitis in children in Taiwan: the important role of hepatitis B virus. J Pediatr 1987;111:34-9.


Long term survival after heart transplantation for doxorubicin induced cardiomyopathy

Maurizio Aricò, Elisa Pedroni, Luigi Nespoli, Mario Viganò, Fulvio Porta, G Roberto Burgio

Abstract

A 10 year old child developed severe cardiomyopathy after combined, multicycle chemotherapy for Ewing’s sarcoma and was treated by heart transplantation with good results. Long term azathioprine and cyclosporin caused only mild impairment of immune function and there were no recurrent infections, local recurrences of the tumour, or distant metastases.

Ewing’s sarcoma is a malignant, round cell tumour of bone that occurs in later childhood and adolescence, which has a poor prognosis. 1, 2 Before the era of combination chemotherapy the five year survival rate was 5 to 10%. 1 Aggressive chemotherapy has resulted in a mean three year disease free survival of almost 60%. 3 This improvement is mainly the result of systemic chemotherapy, with better staging of patients or more efficient radiation regimens playing a small part.

Doxorubicin hydrochloride (Adriamycin) is an essential drug in combined, multicycle chemotherapy, 1, 2 although it is known (together with related drugs) to cause a cardiomyopathy that is usually dose dependent. 4

We describe a child who, having developed a severe cardiomyopathy after combined, multicycle chemotherapy for Ewing’s sarcoma, underwent heart transplantation with good results.

Case report

An 8 year old boy with Ewing’s sarcoma of the pelvis and proximal femur was treated with a four drug combination of chemotherapy (vincristine, cyclophosphamide, dacarbazine, and doxorubicin hydrochloride), plus local irradiation (protocol POG 8095), and conservave surgery. The total dose of doxorubicin that he received was 480 mg/m². Despite regular monitoring of cardiac function by electrocardiography and echocardiograph scanning, severe cardiomyopathy developed 25 months after the diagnosis had been made. Cardiac function rapidly worsened and was soon so impaired that several episodes of congestive failure occurred during the subsequent weeks, leaving the child bedridden.

Twenty nine months after the diagnosis of Ewing’s sarcoma and four months after the onset of cardiomyopathy, the child, by then 10 years old and with no evidence of residual tumour, underwent orthotopic transplantation of a heart from an 8 year old child who had been killed in a car accident. The postoperative course was uneventful. Signs of rejection were monitored by serial myocardial biopsies, and prevented by oral immunosuppressive drugs cyclosporin (5 mg/kg/day), methylprednisolone (2 mg/kg/day), and azathioprine (62.5 mg/day). During the next few months the steroids were reduced to 5 mg daily.

More than three years after transplantation the child is doing well: his heart function is normal, he attends school, and he is able to take part in normal physical activities. Repeated checks indicate that there is no local recurrence or distant metastases. His serum immunoglobulin concentrations were: IgG 14-5 g/l, IgA 4-7 g/l, and IgM 1-8 g/l. IgG subclass values were: IgG1, 81 g/l, IgG2, 1-8 g/l, IgG3, 1-3 g/l and IgG4, 0-3 g/l. Peripheral blood T lymphocyte subsets were: CD3+ 83%, CD4+ 47%, CD8+ 55%, CD11+ 83%, CD20+ 26%, and CD16+ 6%. Lymphocyte proliferative response to phytohaemagglutinin in vitro was 71-7% of normal controls. Delayed type hypersensitivity skin testing evoked no response to any of the challenged antigens.

Discussion

Ewing’s sarcoma is a malignant bone tumour that has a poor prognosis until combined chemotherapy including anthracyclines was introduced. The current five year disease free survival rate is about 60%. Bacci et al recently reported a 7% risk of late relapse after that time, confirming other reports. 3

We have reported a child who, 25 months after the diagnosis of Ewing’s sarcoma, had achieved persistent local and systemic control but suffered from life threatening cardiomyopathy. The decision to attempt heart transplantation was difficult to take. On the one hand it was indicated because of -the poor
Fulminant hepatitis B in an infant born to a hepatitis Be antibody positive, DNA negative carrier.

J Vanclaire, C Cornu and E M Sokal

Arch Dis Child 1991 66: 983-985
doi: 10.1136/adc.66.8.983

Updated information and services can be found at:
http://adc.bmj.com/content/66/8/983

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/